Correction is not control

Correcting myopia and controlling myopia are different clinical acts. A single-vision spectacle lens places the distance image on the fovea and helps the child see clearly. A myopia-control spectacle lens has a second task: it must preserve that central clarity while also changing retinal input in a way that can reduce excessive axial elongation.

This is why axial length has become central in modern myopia management. Refraction remains clinically important, but it can be influenced by accommodation, crystalline lens changes, and measurement conditions. Axial length is closer to the structural risk pathway, and absolute axial-length change is usually more informative than a percentage efficacy value alone (1).

The first generation already set a high bar

Second-generation spectacle lenses should not be presented as a rescue after weak first-generation optics. First-generation designs already showed meaningful group-level efficacy, with DIMS (Defocus Incorporated Multiple Segments)/MiYOSMART demonstrated in the two-year randomized DIMS trial (2) and H.A.L.T./Stellest summarized in the 2025 International Myopia Institute intervention report (3). The next step is therefore not simply more plus. It is a more deliberate retinal signal: where the signal reaches the retina, how strong it is, how much retinal area it covers, how it changes contrast, and whether it remains biologically noticeable during daily viewing.

From defocus to retinal signal-profile design

The original optical model was simple and useful: hyperopic defocus can promote eye growth, and myopic defocus is expected to slow it. That remains relevant, but it is incomplete. Modern spectacle designs also alter local image quality, contrast, the density of treatment zones, and the spatial distribution of light modulation.

This broader view helps distinguish the current platforms. DIMS TED/MiYOSMART iQ emphasizes retinal-topographic redistribution within the DIMS architecture. H.A.L.T. MAX increases lenslet power and asphericity, supporting a dose-response concept within the H.A.L.T. platform. MyoActive asks whether a less repetitive, gaze-dependent retinal signal may mitigate biological adaptation. DOT is included as a contrast-first comparator because it reminds us that growth-modifying optics may work through more than defocus alone.

^{Table 1. What changed from first- to second-generation or emerging myopia-control spectacle lenses}

Note. The table deliberately focuses on design logic; clinical study results are discussed in the text. Manufacturer and conference claims should be treated as provisional until full peer-reviewed publication is available.

Retinal example: DIMS TED/MiYOSMART iQ versus DIMS

Among these design axes, retinal-topographic redistribution can currently be illustrated most directly for DIMS TED/MiYOSMART iQ, because retinal-level SLO recordings compare it with first-generation DIMS. Figure 1 should therefore be read as a visual example of how one second-generation strategy changes the retinal signal pattern. It should not be generalized to H.A.L.T. MAX or MyoActive without comparable retinal-level SLO or contrast measurements.

Early clinical readouts

For H.A.L.T. MAX, peer-reviewed evidence currently comes from an active-comparator contralateral crossover study rather than a single-vision-controlled trial. In that study, increased lenslet power and asphericity produced a broader, more anterior modelled non-focused-light profile. The estimated cumulative one-year axial elongation derived from the two six-month phases was 0.121 mm with H.A.L.T. MAX versus 0.228 mm with standard H.A.L.T., an additional 0.107-mm reduction against the active comparator (4). This supports dose-response optimization within the platform, but it should not be read as direct evidence for a specific retinal-topographic treatment zone.

The most clinically useful iQ data are the age-matched responder results rather than a headline percentage. In the ARVO 2026 age-matched axial-growth analysis by Kaymak et al. (5), mean axial elongation over 12 months was reported as 0.346 mm with single-vision spectacles, 0.20 mm with MiYOSMART, and 0.075 mm with MiYOSMART iQ. In this analysis, the age-matched physiological-growth green zone denotes a physiological axial-growth corridor rather than a relative efficacy percentage. It was reached by 22% of single-vision eyes, 57% of MiYOSMART eyes and 82% of MiYOSMART iQ eyes.

A stricter exploratory stability endpoint of axial change less than or equal to +0.05 mm over 12 months was reached by 4.3%, 36.0% and 57.7%, respectively. These results are clinically intuitive and promising, but they remain conference-level data until the complete peer-reviewed dataset, including variance measures and longer follow-up, is available.

What still needs proof

Several issues remain open. First, durability: impressive six- or twelve-month effects need year two and ideally longer follow-up. Second, adaptation: children must tolerate and wear the lenses, and the retina must not simply treat a repeated treatment pattern as background noise. Third, choroidal change is interesting but should not yet be treated as a validated surrogate endpoint. Rapid choroidal responses may reflect active retinal-choroidal signalling, but long-term axial-length outcomes remain decisive.

Fourth, visual performance matters. Stronger, denser or more central treatment structures must be tested against contrast sensitivity, glare, ghosting, reading comfort, near-work endurance, gaze-dependent performance, and real wearing time. Second-generation lenses should therefore be judged by a balanced standard: biological signal strength, axial-length effect, responder distribution, visual acceptability, and durability.

Conclusion

Second-generation myopia-control spectacle lenses are best understood as a move from correction plus defocus toward biologically targeted retinal signal-profile design. DIMS TED/MiYOSMART iQ illustrates retinal-topographic redistribution within the DIMS platform; H.A.L.T. MAX illustrates dose-response optimization within a lenslet platform; MyoActive raises the question of adaptation management; and DOT keeps contrast modulation in the mechanistic discussion.

The useful clinical message is strong but careful: newer spectacle lenses are not merely stronger versions of older optics. They are attempts to design retinal signals more deliberately. The next evidence step is not another slogan, but robust peer-reviewed data showing durability, visual acceptability, and responder distributions over time.